"At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research," U.S.

After exiting the FDA less than two weeks ago for unclear reasons, Vinay Prasad is once again director of the Center for ...

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to ...

Vinay Prasad, previously critical of U.S. COVID-19 policies, has returned to his role managing vaccine and gene therapy regulation at the FDA, days after his departure. His leadership saw controversy ...

Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...

Mum of Newry boy Alfie casts doubt on ability of NI health service to roll out new medicine, after Belfast Trust says no due ...

Last month Claire Ellis, aged 34, a teacher from Doncaster, set off from her home to cycle 100km in support of her son Declan ...

To accommodate this meeting, the Company has rescheduled the release of its financial results for the second quarter ended June 30, 2025, to Monday, August 11, 2025, after the market close. Management ...

On Saturday 12 July, Claire Ellis, 34, a teacher from Doncaster set off from her home to cycle 100km in support of her son ...

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

Edgewise Therapeutics Inc., (Nasdaq: EWTX), a Boulder-based muscle-disease biopharmaceutical company, maintained a strong cash balance in the second quarter as it proceeds with trials for treatment of ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.